Equities

Incanthera PLC

INC:NXX

Incanthera PLC

Actions
  • Price (GBX)17.31
  • Today's Change-2.44 / -12.35%
  • Shares traded146.96k
  • 1 Year change+170.47%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Incanthera plc is a United Kingdom-based dermatology and oncology therapeutics company. The Company's is focused on developing a range of dermatological applications utilizing its unique formulation and delivery technologies to meet the unmet needs in the skincare market. Skin + CELL is the Company’s luxury skincare brand utilizing the advanced formulation and delivery expertise, to bring scientifically proven formulations to cosmetics. Skin + CELL's formulations, enriched with targeted bioactive B3 (an activated form of niacinamide) are delivered directly into the skin's cells to optimize and protect cellular health, energy and protective capabilities. Skin + CELL's luxury skincare range extends across face, body, hand, face serum and eye serum.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-1.48m
  • Incorporated2017
  • Employees8.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Synairgen plc0.00-9.99m11.60m30.00--0.7266-----0.0496-0.04960.000.07930.00----0.00-41.40-54.75-48.86-60.72-------83,247.62----0.00------63.74--0.00--
Proteome Sciences plc5.03m-2.44m11.81m35.00------2.35-0.0083-0.00830.017-0.01040.42093.893.04143,657.10-20.45-1.22----32.7654.53-48.59-2.200.2667-2.031.29---35.3710.52-284.38--126.22--
Chill Brands Group PLC146.62k-3.64m12.40m2.00------84.60-0.0142-0.01420.0006-0.00240.03190.09920.363973,310.00-79.21-72.55-141.46-105.3553.05---2,485.30-1,625.460.6499-8.481.17---86.73-50.8923.50---35.95--
Provexis plc598.08k-496.59k13.58m2.00--13.54--22.70-0.0002-0.00020.00030.00040.67173.042.95299,040.00-55.78-48.82-41.86-33.6846.7286.14-83.03-97.641.96--0.00---8.5110.58-71.79------
Abingdon Health PLC5.34m-2.24m13.94m82.00--7.38--2.61-0.0184-0.01840.04390.01490.89787.674.7465,170.73-37.55-51.31-58.04-79.8557.3533.16-41.82-139.641.59--0.3572--42.68--83.77------
Shield Therapeutics PLC13.09m-33.29m14.47m73.00--0.9624--1.11-0.0458-0.04580.01810.01920.3473.651.31179,246.60-88.29-56.68-136.30-67.4430.7852.20-254.44-365.892.04-30.010.5739--137.951.9533.13---2.50--
Genincode PLC1.72m-6.73m15.48m28.00--1.76--9.02-0.0703-0.07030.01790.04970.16816.362.8861,285.71-65.92---72.37--47.55---392.31--5.85--0.0632--23.92---34.21------
Destiny Pharma PLC0.00-5.66m15.49m19.00--1.68-----0.0624-0.06240.000.09650.00----0.00-60.33-54.32-67.28-59.97------------0.00------13.02--35.39--
LungLife AI Inc36.32k-4.27m15.81m15.00--0.8784--435.41-0.1677-0.16770.00140.24510.0038--0.28312,421.20-44.11---50.09--100.00---11,767.39------0.0419--91.67--28.83------
OptiBiotix Health PLC689.10k-13.17m17.63m3.00--1.75--25.58-0.1489-0.14890.00780.10290.04262.281.25229,700.00-81.3517.83-83.4318.6649.3154.87-1,911.88190.543.24-0.0890.00---79.3519.05-58.686.2830.03--
Oncimmune Holdings PLC1.15m-6.15m18.16m56.00--27.65--15.77-0.08590.05070.01590.00890.12391.080.5941---66.15---131.46--68.75---533.94--3.75-1.960.8897--------------
Incanthera PLC0.00-1.48m18.86m8.00---------0.0192-0.01920.00-0.00860.00----0.00-373.20-101.74---132.88---------------------36.11------
Skinbiotherapeutics PLC161.65k-2.88m19.54m11.00--5.08--120.86-0.0165-0.01650.00090.01920.05220.88710.418114,695.45-93.07-52.07-115.26-57.3362.90---1,784.70-4,694.376.48-379.780.0259--76.65---1.52--18.00--
Hemogenyx Pharmaceuticals PLC0.00-6.69m19.99m17.00--6.21-----0.0061-0.00610.000.00240.00----0.00-101.47-82.19-112.85-95.97-----------28.030.5144-------68.14--36.68--
Verici DX PLC15.00k-8.85m20.04m14.00--2.67--1,335.91-0.052-0.0520.000090.0310.0013--0.11521,000.06-77.76---92.28--84.21---59,015.79------0.0232-------36.94------
Oxford Biodynamics PLC510.00k-10.83m24.14m45.00--2.59--47.33-0.0729-0.07290.00350.02990.03710.79870.33211,333.33-78.82-39.72-105.32-45.5252.16---2,122.75-1,324.621.72-7.500.5154--231.17-15.53-61.34---1.60--
Data as of May 17 2024. Currency figures normalised to Incanthera PLC's reporting currency: UK Pound GBX

Institutional shareholders

17.63%Per cent of shares held by top holders
HolderShares% Held
Odd Asset Management Ltd.as of 23 Apr 202416.24m17.63%
Data from 30 Apr 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.